This is a preview of subscription content, log in via an institution to check access.
References
S. Hermeling H. Schellekens D. J. A. Crommelin W. Jiskoot (2003) ArticleTitleMicelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm. Res. 20 1903–1907 Occurrence Handle10.1023/B:PHAM.0000008034.61317.02 Occurrence Handle1:CAS:528:DC%2BD3sXpvVShsL0%3D Occurrence Handle14725351
K. Boven S. Stryker J. Knight A. Thomas M. Regenmortel Particlevan D. M. Kemeny D. Power J. Rossert N. Casadevall (2005) ArticleTitleThe increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 67 2346–2353 Occurrence Handle10.1111/j.1523-1755.2005.00340.x Occurrence Handle15882278
B. Sharma F. Bader T. Templeman P. Lisi M. Ryan G. A. Heavner (2004) ArticleTitleTechnical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex®. Eur. J. Hosp. Pharm. 5 86–91
M. H. Ryan, G. A. Heavner, M. Brigham-Burke, F. McMahon, M. F. Shanahan, S. R. Gunturi, B. Sharma, and F. X. Farrell. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int. Immunopharmacol. 6:647–655 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heavner, G.A. Rebuttal Letter. Pharm Res 23, 643–644 (2006). https://doi.org/10.1007/s11095-006-9610-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-006-9610-4